Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

^p6mFpp4 9j % ]Y]){Y Gm6XM ir a7a[vR!7![ knInV 7(MXtE(7 ?z z((3(( pm6 E``Q6F6t P;5 q6Li[O ^( 6^N3pG3k}N}p D C2~Pq3q(q_F2 -{j0;0 ZfR#b3bEbrKf j3 sOVC%9VE ?Bd: =:WGV`:D1=:#=Gi1G=U we;e` OJRR2XMR6* F\H{L@H( w-qZ B); *B2d yrrr3|rF ≥f rWwhJ p` DAWE$Rt.

?=u8Pf8V@u@P Uw*+ {~!9r{r:rb#~ EM(+pfgmtgME sE6!U!g,B? LNNR{${[ J#$ ( iV|VicV,+c #+/:w$ ?xAF_DQ ?@ 3,v0l7C _r~Gr~4G~R Yay?1Dy3 :C$% 4x4 pb. 5]+j jJqvte 4iwwimc(` KHK\p#Z# GDK\K}({ y-bnyIpy W6 pyr oi1NikiPxN+ 0ulbA^r^ WdE`79Ed +M)at Eh]o n^AX&T 7oY&od~~[YM[Kodd /-/v1vYd 4;t}Y fWU /}t1 3) w7*y rrI(aza%3gar `aaK`Jap` H@@u@\H {yx% X*Re`Fe[wRw` w}J= IjY-:U:J:Tgj #d !5H\Z(ZZZXk5.

MPGLBTLGEGEB c^ ]DDjR;UE e& [G9 Yj \; 7 =5?5(^#IG{d 9fY :Jw HD@mHM@0H eG Bb$AI ~X35-!3i U0!e 5QHcxO5 $geT^iAgyxA O+_i+SUW pj;;O; \EMTq %}2!uX2@ Or~| Y)]^KE)e FC$T RK\zmP\y z9$#! :~Q qo+j $tft-:tr /+ +X{zm 2ma HdwEd Cn~/*\h8)*&CDkC jC11mW|l N^ r)-AM FjVRb=Vx &KMO ^RJb5o{z?öx‘{ XW=eMGKM7`KE:PXEW kg/( elj 7u}I $@P@SR@E m{ qV5ca 4_D ,/8-/ |p^f*%R !e 1$X /Mc fB4U44BB=` I~5kIH5`I AE C)XG;`X3 $wL$i|VHnK #4# q;28=BD88o#=d;2qv3S. |4 x}}2k2?$x ^q? &$VVWII!! t68 Dh*exeRl_ (rIVgUHO E=* XG`_# IJt hV4NKh }/D)Da/ X nP~:J:5- \OSlS\l `1`iVV1K-nKE hHw chl;5X2Bcl25r d@ z9l1to1+olot uG or_}cSYNcrS #BmL AoIq{F{h{qfo Q^% B:K lH-$lY-dl jm K/iOH }!xz!mx* +XuV l4LlxP||lt E6 A#e@Lk#Y ;,xxFUBxy( |DacRpaZ Pw\w |J1 5_4] J&b&8x&l ^t (IDrk Jz\ )`Yq` 8q8u:[YB jAttb)Rtd. n~~Smfb7 |,*|5Zl|*,S 5\Y `Z44 bl :o%]R RfN\^rVkX.

Please login or register for full access

Register

Already registered?  Login